Teclistamab-cqyv Shows Promise in Relapsed/Refractory Multiple Myeloma Following 4 Prior Lines of TherapyByEmily Viehl, PharmD, BCOPFebruary 16th 2023Because of CRS and neurologic toxicity risk, the therapy is available through a REMS program.